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Question: Is local anesthetic thoracoscopy and talc poudrage more effective than 
chest drain and slurry at inducing pleurodesis in those with malignant pleural 
effusion. 
Findings: In this randomized clinical trial that included 330 patients, 
thoracoscopic talc poudrage, compared with bedside talc slurry, resulted in no 
significant difference in the rate of pleurodesis failure at 90 days (22% vs 24%, 
respectively). 
Meaning: Among patients with malignant pleural effusion, there was no 
significant difference in rate of pleurodesis failure between talc poudrage and talc 
slurry, however the study may have been underpowered to detect small but 
potentially important differences. 
Importance  Malignant pleural effusion (MPE) is challenging to manage. Talc 
pleurodesis is a common and effective treatment. There are no reliable data, 
however, regarding the optimal method for talc delivery, leading to differences in 
practice and recommendations. 
Objective  To test the hypothesis that talc poudrage during local anesthetic 
thoracoscopy was more effective than talc slurry via chest tube in leading to 
successful pleurodesis. 
Design, Setting, and Participants  Open-label, randomized clinical trial 
conducted at seventeen hospitals in the United Kingdom. 330 participants were 
enrolled from August 2012 to April 2018 and followed until October 2018. 
Patients were eligible if they were aged over 18 years, had a confirmed diagnosis 
of MPE needing pleurodesis and were sufficiently fit for local anesthetic 
thoracoscopy. Main exclusions were the need for pleural tissue or evidence of 
non-expandable lung. 
Interventions  166 patients were allocated to the intervention group and had 4g 
talc poudrage at thoracoscopy under moderate sedation. 164 patients were 
allocated to the control group and had bedside chest tube insertion followed by 4g 
sterile talc slurry. 
Main Outcomes and Measures  The primary outcome was pleurodesis failure up 
to 90 days after randomization. Secondary outcomes included pleurodesis failure 
at 30 and 180 days, time to pleurodesis failure, number of nights in hospital over 
90 days, patient-reported thoracic pain and dyspnea at 7, 30, 90 and 180 days, 
health-related quality of life at 30, 90 and 180 days, mortality, and percentage 
radiographic opacification at drain removal, 30, 90 and 180 days. 
Results  Among 330 patients who were randomized (mean age 68 years; 181 
(55%) female), 320 (97%) were included in the primary outcome analysis. At 90 
days, pleurodesis failure rate was 36/161 (22%) with poudrage and 38/159 (24%) 
with slurry (adjusted odds ratio [poudrage vs slurry] 0.91, 95% confidence interval 
0.54-1.55, P = .74; difference in percentage points –1.8, 95% confidence interval –
 
 
10.7 to 7.2). No statistically significant differences were noted in any of the 24 
pre-specified secondary outcomes. 
Conclusions and Relevance  Among patients with malignant pleural effusion, 
local anesthetic thoracoscopic talc poudrage, compared with bedside talc slurry 
through chest tube, resulted in no significant difference in the rate of pleurodesis 
failure at 90 days. However, the study may have been underpowered to detect 
small but potentially important differences. 
Trial Registration  clinicaltrials.gov Identifier: ISRCTN47845793. 
Introduction 
Malignant pleural effusion (MPE) is a common condition which may be 
associated with a variety of cancer subtypes. For many, associated dyspnea and the 
resultant functional disability pose a significant management challenge. 
Although ambulatory drainage options are becoming common in some 
regions,1,2 these are not available to most patients worldwide and do not reliably 
lead to cessation of fluid production (pleurodesis).1,3 In addition, many patients or 
clinicians prefer to pursue pleurodesis as the primary management strategy.4 As 
such, pleurodesis remains the default for the majority with MPE.5-7 Meta-analysis 
and large prospective study data strongly support sterile talc powder being the 
optimum agent for inducing pleurodesis,8 with graded talc being safest.9,10 
Talc may be delivered at the bedside through an intercostal chest tube in the 
form of a slurry or sprayed directly onto the pleural surface during a thoracoscopic 
procedure (poudrage). Pulmonologist-led thoracoscopy under local anesthetic and 
moderate sedation (also known as pleuroscopy) is now an established alternative 
to thoracoscopy under general anesthesia,11 although most previous randomized 
studies regarding pleurodesis have utilized the latter, meaning existing data are 
now poorly-representative of current practice.8 
There is no consensus on whether slurry or poudrage is the more effective 
technique for delivering talc in MPE and thus clinical practice and 
recommendations are inconsistent.4,12 Previous studies have been inconclusive or 
criticized due to small sample sizes; the use of surrogate or non-patient-focused 
 
 
outcomes; and high rates of serious adverse events related to the use of ungraded 
talc formulations.13-15 
This study, the TAPPS trial, was designed to test the hypothesis that talc 
poudrage during local anesthetic thoracoscopy was more effective than slurry via 
chest tube at inducing pleurodesis in patients with MPE. 
Methods 
Trial Design 
The TAPPS trial was a randomized, open-label, parallel-group superiority 
trial of two established interventions for pleurodesis. Trial design, implementation, 
analysis, and manuscript preparation were performed by the trial investigators. 
Study oversight was provided by North Bristol NHS Trust, the trial steering 
committee, and an independent data monitoring committee. Ethical approval was 
provided by the National Research Ethics Service Committee (12/NW/0467). See 
online supplement sections 1a to 1c. 
Trial Setting and Participants 
Patients were screened and recruited from seventeen hospitals in the United 
Kingdom. All participants provided written informed consent to enrolment and to 
the allocated intervention. All sites had established, pulmonologist-led, local 
anesthetic thoracoscopy services and had experience of providing both trial 
interventions. 
Eligible patients were required to have a MPE which was either: proven 
histocytologically; an unexplained effusion in the context of proven cancer; or 
suggested by pleural changes consistent with malignancy on cross-sectional 
imaging. They were required to be able to tolerate thoracoscopy under moderate 
sedation and have an estimated survival of greater than three months. Patients 
were ineligible if they were less than eighteen years old; required a thoracoscopy 
for diagnostic purposes (as, ethically, they could not then be randomized to receive 
chest tube and slurry); were pregnant or lactating; had known pleural 
 
 
characteristics which would normally contraindicate pleurodesis (such as lung 
entrapment or fluid loculation, both as judged by the local recruiting clinician); did 
not have sufficient fluid present to safely perform thoracoscopy without inducing a 
pneumothorax, or had contraindications to any study intervention. See online 
supplement sections 1day and 1e. 
Randomization 
Participants were randomly assigned in a 1:1 ratio through a centralized, 
web-based system using a computer-generated minimization algorithm (with a 
random component of 80%).16 The minimization algorithm minimized the 
imbalance between treatment groups with respect to the minimization factors, 
underlying malignancy (mesothelioma, breast cancer, lung cancer, other) and 
World Health Organization (WHO) performance status (0-1, 2-3). The study was 
conducted on an open-label basis and thus participants, clinicians, and data-
collectors were aware of treatment allocation. Patient blinding was not practical 
due to the inherent differences between the interventions and the use of sham 
procedures was not felt to be ethical given the limited availability of interventional 
sessions for thoracoscopy at most participating hospitals. Trial procedures were 
undertaken within 72 hours of randomization. See online supplement section 1h. 
Interventions 
Participants in the intervention (poudrage) group underwent local anesthetic 
thoracoscopy under moderate sedation. Following complete drainage and 
inspection of the chest cavity, four grams of dry sterile graded talc powder 
(Steritalc, Novatech, La Ciotat, France) were insufflated into the pleural space 
with a view to achieving even pleural coverage. A 16-24 French gauge chest tube 
was inserted at the end of the procedure and a chest radiograph performed 18-24 
hours later. 
Those in the control (slurry) group initially received a 12-14 French gauge 
chest tube inserted under ultrasound guidance and local anesthetic. Insertion was 
 
 
performed or supervised by clinicians who were experienced and fully 
independent practitioners. A chest radiograph was performed 18-24 hours post-
insertion and those without unexpanded lung or significant residual pleural 
opacification were given four grams of sterile graded talc, instilled intrapleurally 
in the form of a slurry. 
Patients in both treatment groups received thoracic suction if tolerated, 
applied via the chest tube for a minimum of 24 hours. Unless clinically indicated, 
tubes could not be removed within 24 hours of talc or if fluid output exceeded 250 
mL per day. Following tube removal, discharge from hospital was left to the 
discretion of local investigators. See eFigures S1 and S2 in Supplement, and 
section 1i in the online supplement. 
Follow-up 
Patients were followed up until 180 days after randomization, or death. 
Trial visits were conducted at the hospital at 30, 90, and 180 days after 
randomization. Any patient who was noted to have worsening dyspnea was 
recommended to undergo chest radiography as an initial assessment, with the 
presence of progressive pleural opacification leading to either ultrasound or CT to 
identify fluid. If fluid was confirmed on the same side as the previous trial 
intervention, and the chest radiograph showed greater than one third hemithorax 
opacification by visual estimation, the clinician could undertake any required 
interventions to relieve symptoms. However, in cases where the degree of 
radiographic opacification was potentially more contentious, defined as less than 
one third of the hemithorax by visual estimation, the clinician was required to 
discuss the need for further intervention with a second clinician who was to 
remain blind to treatment group. 
Outcomes 
The primary outcome was pleurodesis failure at 90 days post-
randomization. Pleurodesis failure was recorded if the patient underwent any of 
 
 
the following interventions on the same side as the trial intervention during the 
follow up period: any thoracentesis of ≥100 mL (threshold chosen to distinguish 
between a low-volume ‘diagnostic’ procedure, which would not aim to influence 
symptoms, and a larger-volume ‘therapeutic’ procedure); chest tube insertion for 
fluid management; insertion of an indwelling pleural catheter; or thoracoscopy of 
any kind. If any of these were deemed necessary by the participant’s clinician, but 
were not done because the patient declined, or had died, this was recorded as 
treatment failure. In all other cases, if a patient died during follow-up then no 
failure was recorded. See online supplement section 1l. 
Secondary outcomes included pleurodesis failure at 30 and 180 days post-
randomization; measured percentage radiographic pleural opacification after tube 
removal and at 30, 90, and 180 days post-randomization;17 all-cause mortality up 
to 180 days post-randomization; time to pleurodesis failure within 180 days; 
cumulative number of nights spent in hospital post-randomization; self-reported 
health-related quality of life at 30, 90, and 180 days post-randomization (EuroQoL 
Group 5-Dimensions 5-Level Questionnaire (EQ-5D-5L),18 responses to which 
were converted into a utility score ranging from −0.59 to 1.00,19 and scores on the 
visual-analogue scale range from 0 to 100, with higher scores indicating better 
quality of life) and the RAND Short Form Health Survey (SF-36; with individual 
domains’ scores transformed on to a scale from 0 (worst health) to 100 (best 
health) before being converted into a SF-6D utility score ranging from 0.257 to 
1.00, with higher scores indicating better quality of life);20-22 and self-reported 
chest pain and dyspnea measured using a visual-analogue scale at 7, 30, 90, and 
180 days (VAS; scales running from 0 to 100mm, with a score of 0 indicating the 
complete absence of symptoms and 100 the maximum possible level of 
symptoms). The minimal clinically important difference (MCID) for dyspnea in 
malignant pleural effusion using 0-100mm VAS scale is 19mm (95% CI, 14 to 
 
 
24mm), with MCIDs for other measures not established in this population.23 See 
online supplement section 1o. 
Exploratory outcomes, added during trial recruitment but before data were 
available to investigators, were percentage radiographic pleural opacification 
(assessed categorically as no visible fluid, 1%-24% opacification, 25%-49% 
opacification, and 50% or more opacification) at drain removal, 30, 90 and 180 
days post randomization; and degree of visible lung entrapment on chest 
radiograph at 180 days (categorized as no lung entrapment, minor (1%-24% 
entrapment), moderate (25%-49%), or severe (50% or more)). See online 
supplement section 1p. 
Adverse events were recorded at each trial visit. Serious adverse events 
were assessed locally before being verified independently by the Sponsor, and 
subsequently by the Chief Investigator and the independent data monitoring 
committee.24 Final classification of all adverse events was performed by an 
independent third party who was blind to treatment allocation. See online 
supplement section 3. 
Sample Size and Statistical Analysis 
Previous literature suggested that patients with performance scores of 2 or 
better would expect to have a pleurodesis failure rate of 10% using talc poudrage 
and 30% using talc slurry.25 Thus, at the 5% significance level, in order to detect 
an absolute 15% difference in pleurodesis failure rate (assuming failure rates of 
10% with poudrage and 25% with slurry, odds ratio 0.33) with 90% power, a total 
of 325 patients (allocated in a 1:1 ratio) was required, accounting for 10% loss to 
follow-up. The final recruitment target was rounded up to 330 patients. 
All participants with a recorded outcome were analyzed according to their 
allocated treatment group; participants with missing outcome data were 
excluded.26 All analyses were adjusted for the minimization variables (underlying 
malignancy, WHO performance status 0-1 vs 2-3),27 with analysis of VAS scores 
 
 
also adjusted for baseline values. Pleurodesis failure outcomes (including the 
primary outcome) and mortality were analyzed using a logistic regression model. 
A mixed-effects linear regression model was used to analyze radiographic pleural 
opacification, thoracic pain and dyspnea. A competing risk time-to-event 
regression model (with mortality as the competing risk) was used for time to 
pleurodesis failure within 180 days. Number of nights in hospital was analyzed 
with a negative binomial regression model. Quality of life measures were analyzed 
using linear regression. 
Sensitivity analyses were performed to assess robustness of results under 
different missing data assumptions.26,28 Additional post hoc sensitivity analyses 
were performed for the primary outcome, including a competing risk time-to-event 
model for pleurodesis failure at 90 days, an unadjusted analysis, and a mixed-
effects logistic regression model which included a random-intercept for study site. 
Subgroup analyses for the primary outcome were performed using interaction 
tests. Analyses performed were anti-cancer treatment vs no treatment at baseline; 
WHO performance status 0 vs 1 vs 2 vs 3; steroid treatment vs no treatment at 
baseline; pleurodesis in last 30 days vs no pleurodesis; and primary malignant 
diagnosis of breast cancer vs lung cancer vs mesothelioma vs other). All P values 
were 2-sided and considered significant at the 0.05 level. Because of the potential 
for type 1 error due to multiple comparisons, findings for analyses of secondary 
endpoints should be interpreted as exploratory. 
No interim analyses were planned or conducted. Analyses were performed 
using Stata software version 15 (StataCorp, TX, USA). See online supplement 
sections 1f, 1g, 1j, to 1q; eTables S1 and S2 in Supplement for further details of 





Recruitment and follow-up took place between August 2012 and April 
2018. The target of 330 was achieved after 1121 patients were assessed for 
eligibility, of whom 284 did not meet the trial entry criteria and 322 declined to 
participate. 166 patients were allocated to talc poudrage and 164 to talc slurry and, 
of these, 161 (97%) and 159 (97%) respectively were included in the analysis of 
the primary outcome. 161/166 (97%) in the poudrage group and 144/164 (89%) in 
the slurry group received talc as intended (Figure 1). 
Baseline and Post-drainage Characteristics 
The treatment groups were well-matched at baseline, although fewer 
patients in the poudrage group were receiving chemotherapy at enrolment (15/166, 
9%) than in the slurry group (33/164, 20%). Most patients were of performance 
score 1 or 2 (258/330, 78%) and had either lung or breast cancer (212/330, 64%). 
On chest radiograph 18-24 hours after fluid drainage, 85/106 (80%) in the 
poudrage group had fully-expanded lung compared to 90/109 (83%) in the slurry 
group. Later, at tube removal, full expansion was seen in 92/105 (88%) in the 
poudrage group and 90/98 (92%) in the slurry group. 
Further details are provided in Table 1; eTables S3-S8 and S19 in 
Supplement. 
Primary Outcome 
In the primary outcome analysis, at 90 days post randomization, failure rate 
was 36/161 (22%) in the poudrage group and 38/159 (24%) in the slurry group 
(adjusted odds ratio (OR) [poudrage vs slurry] 0.91, 95% confidence interval (CI) 
0.54 to 1.55, P = .74; difference in percentage points –1.8, 95% confidence 
interval –10.7 to 7.2) (Figure 2). There were 27 deaths prior to failure (17%) in the 
poudrage group, and 34 (21%) in the slurry group. A post hoc sensitivity analysis 
which incorporated mortality as a competing risk showed similar results to the 
 
 
primary analysis (hazard ratio 0.91, 95% CI, 0.58 to 1.43; eTable S23 in 
Supplement). Additional sensitivity analyses supported these results (eTables S21 
and S22; eFigure S3 in Supplement). For more details regarding primary outcome 
results, including prespecified subgroup analyses, see eTables S9, S10 and S20 in 
Supplement. 
Additional Outcomes 
Additional outcome data are summarized in Table 2; eTables S11-18, S30-
32; eFigures S4-6. 
Pleurodesis Failure and Time to Pleurodesis Failure 
At 30 days post randomization, 16/161 (10%) receiving poudrage had 
failed pleurodesis compared to 22/159 (14%) in the slurry group (OR 0.69, 95% 
CI, 0.34 to 1.37, P = .29; difference in percentage points –1.7, 95% confidence 
interval -6.0 to 2.6). At 180 days, failure rates were 46/161 (29%) in the poudrage 
group compared to 44/159 (28%) in the slurry group (OR 1.05, 95% CI, 0.63 to 
1.73, P = .86; difference in percentage points 0.0, 95% confidence interval -9.3 to 
9.3). 
No difference was found between the groups in time to pleurodesis failure 
(hazard ratio 1.01; 95% CI, 0.67 to 1.52). 
All-cause Mortality 
No significant difference in mortality was observed up to 180 days. 66/165 
(40%) patients died in the poudrage group and 68/163 (42%) patients died in the 
slurry group (OR 0.91, 95% CI, 0.58 to 1.44, P = .35; difference in percentage 
points –1.1, 95% CI, −11.3 to 9.1). 
Hospital Stay 
Up to 90 days, patients receiving poudrage spent a mean of 12.1 (95% CI, 
10.1 to 14.1) nights in hospital after randomization (inclusive of the initial stay for 
trial treatment), with those receiving slurry spending 10.8 (9.3 to 12.4) nights (rate 
 
 
ratio 1.11, 95% CI, 0.89 to 1.37, P = .35; difference in means 1.2, 95% CI, −1.3 to 
3.7)). 
Chest Pain and Dyspnea 
No significant between-group differences were seen in chest pain or 
dyspnea at 7, 30, 90 or 180 days post-randomization (See Table 2). 
Radiographic Pleural Opacification 
At tube removal, mean radiographic pleural opacification was 16 (95% CI, 
14 to 19) percent in the poudrage group and 17 (95% CI, 14 to 20) percent in the 
slurry group (difference in means -0.8, 95% CI, −4.5 to 2.9, P = .66). No 
significant differences in opacification were subsequently seen between treatment 
groups at 30, 90, or 180 days post randomization (See Table 2). 
Health-related Quality of Life 
No significant between-group differences in health-related quality of life 
were seen at any trial follow-up point using either the SF-36 or the EQ-5D-5L 
questionnaires (See Table 2). 
Adverse Events 
Details of adverse events are shown in Table 3 (and eTables S24-29 in 
Supplement). A total of 179 and 152 adverse events were recorded in the poudrage 
and slurry groups respectively. There were no deaths attributable to either of the 
trial interventions. Excluding dyspnea due to fluid reaccumulation, the commonest 
adverse events were pneumonia/lower respiratory tract infection (19 in slurry 
group, 25 in poudrage group) and pneumothorax unrelated to the trial 
interventions (18 slurry, 15 poudrage). More episodes of pleural infection were 
noted in the poudrage group (6, vs 0 in slurry group). Tube dislodgement was 




In this randomized clinical trial that compared the pleurodesis efficacy of 
talc poudrage, delivered at thoracoscopy with moderate sedation, against that of 
chest tube and talc slurry in malignant pleural effusion, there was no significant 
difference between the treatments in the primary outcome of pleurodesis failure 
rate at 90 days. Sensitivity analyses supported this finding. No significant 
differences in secondary outcome measures were noted, including pleurodesis 
failure rate at 180 days or all-cause mortality. 
Previous studies addressing the optimal method for talc delivery have been 
considered inconclusive, resulting in inconsistency in both practice and 
recommendations.4,12 For example, the study by Dresler et al, which analyzed 482 
patients, also found no significant difference between poudrage and slurry (failure 
rates 22% vs 29% respectively at 30 days) but required patients to be well enough 
to undergo general anesthetic and video-assisted thoracoscopic surgery to perform 
poudrage; noted high respiratory complication rates as a result of ungraded talc 
being used; and adopted a primary outcome for pleurodesis which was assessed 
radiologically, rather than in a clinically-oriented fashion.14 
It has previously been shown that talc slurry can be administered safely and 
effectively on an outpatient basis through an indwelling pleural catheter.29 With 
that approach, pleurodesis failure was substantially more common than noted here, 
at 57% at 35 days post randomization, although no direct comparison has ever 
been made with the inpatient methods described in the current study.30 
Aside from perceived benefits in pleurodesis success, a clinician’s choice of 
talc slurry or poudrage has traditionally been based on several factors, including 
whether a chest tube has already been inserted; local infrastructure, experience and 
training; and patient phenotype with regards to fluid production and accessibility. 
Importantly, however, increasing priority is now given to recognizing patient 
choice in MPE management.6,7,31 These data lend further support to the 
 
 
development of flexible treatment pathways, with intervention for MPE tailored to 
the wishes, needs and risks of the individual patient with the knowledge that 
treatment effectiveness is unlikely to be affected by how talc is delivered.7,30,32 
Limitations 
This study has several limitations. First, participants were required to be 
able to tolerate a thoracoscopy under moderate sedation, meaning the results may 
be less generalizable to frailer patients. Second, the study was conducted on an 
open-label basis and thus it was possible that decisions regarding the need for 
further interventions during follow-up (the primary outcome) could have been 
influenced by clinicians’ knowledge of the randomized procedure, although a 
requirement for blinded assessment of small effusions attempted to mitigate this 
risk. Third, the trial was powered to detect a 15% difference between the treatment 
groups and was therefore underpowered to detect smaller differences which might 
be considered clinically relevant. Fourth, the study follow-up duration of 180 days 
may not have been long enough to inform long term care decisions in patients with 
MPE of certain subtypes, especially breast cancer or mesothelioma, who have 
longer median survival.33,34 
Conclusions 
Among patients with malignant pleural effusion, local anesthetic 
thoracoscopic talc poudrage, compared with bedside talc slurry through chest tube, 
resulted in no significant difference in pleurodesis failure rate at 90 days. 
However, the study may have been underpowered to detect small but potentially 
important differences. 
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Figure 1. CONSORT diagram showing screening, enrollment and 
treatment allocation of participants 
WHO = World Health Organization 
Figure 2. Kaplan-Meier curve for pleurodesis failure to 180 post-
randomization 
Primary outcome analysis took place at 90 days post randomization. At 
this point, 36/161 (22%) in the poudrage group had experienced 
pleurodesis failure compared with 38/159 (24%) in the slurry group 
(adjusted odds ratio (OR) 0.91, 95% confidence interval (CI) 0.54 to 1.55, 
P = .74). At 180 days, failure rates were 46/161 (29%) in the poudrage 
group compared to 44/159 (28%) in the slurry group (OR 1.05, 95% CI, 
0.63 to 1.73, P = .86). 
 
 
Table 1. Summary of Baseline Characteristics 
Characteristic Summary Measure, No. (%) 
Thoracoscopy and 
Poudrage (N = 166)a 
Chest Tube and 
Slurry (N = 164)a 
Age, mean (SD), y 68 (11) 68 (12) 
Female 96 (58) 85 (52) 
Smoking status   
  Current smoker 13/165 (8) 12 (7) 
  Ex-smoker 104/165 (63) 98 (60) 
  Never smoker 48/165 (29) 54 (33) 
WHO score   
  0 17/165 (10) 18 (11) 
  1 82/165 (50) 81 (49) 
  2 46/165 (28) 49 (30) 
  3 20/165 (12) 16 (10) 
Pleural interventionb in previous three 
months 
117 (70) 121 (74) 
Pleurodesis attempt in previous month 2 (1) 3 (2) 
Length of symptoms, wk   
<1 5 (3) 6 (4) 
  1-3 40 (24) 35 (21) 
>3 121 (73) 123 (75) 
Percentage radiographic (x-ray) pleural 
opacification, mean (SD) [No.] 
54 (20)c [37] 47 (20)c [37] 
Underlying cancer type   
  Lung 59 (36) 54 (33) 
  Breast 50 (30) 49 (30) 
  Mesothelioma 15 (9) 19 (12) 
  Other 15 (9) 5 (3) 
  Lower GI 6 (4) 9 (5) 
  Kidney 5 (3) 11 (7) 
  Ovarian 6 (4) 7 (4) 
  Upper GI 4 (2) 4 (2) 
  Unknown 3 (2) 4 (2) 
  Lymphoma 3 (2) 2 (1) 
Medications   
  Oral corticosteroid 22 (13) 24/163 (15) 
  Non-steroidal anti-inflammatory 21 (13) 29/163 (18) 
  Other analgesic 118 (71) 107/163 (66) 
Cancer treatment   
  Radiotherapy 48 (29) 40/163 (25) 
  Chemotherapy 15 (9) 33/162 (20) 
  Cancer-modulating hormone therapy 27 (16) 17/163 (10) 
  Anti-cancer monoclonal antibodies 5 (3) 6/163 (4) 
  Other anti-cancer therapy 2 (1) 6/163 (4) 
  Anticoagulant therapy 29 (17) 35/163 (21) 
aUnless otherwise stated. 
 
 
bPleural interventions were: diagnostic or therapeutic thoracentesis, image guided biopsy, 
intercostal drain insertion, indwelling pleural catheter insertion, local anesthetic or 
surgical thoracoscopy, other. 
cChest radiography was not required at time of enrolment unless clinically indicated. 
Suitability for study entry was typically assessed using thoracic ultrasound. 
WHO score = World Health Organization performance status score, measured as either 0, 
1, 2, 3 or 4, with 0 indicating a fully active individual with no functional limitation; 1 
indicating limitation only when undertaking strenuous activity; 2 indicating limitation 
when undertaking any work activity but ambulatory and able to self-care; 3 indicating 
restriction such that only limited self-care is possible; and 4 indicating complete disability 
with no ability to self-care. 
See eTable S3 in Supplement for full baseline characteristics data. 
 
 
Table 2. Summary of Secondary Outcome Results 
 Thoracoscopy 
and Poudrage (N 
= 166)+ 
Chest Tube 










No. (%) of patients at 
30 d 
16/161 (10) 22/159 (14)   
  Odds ratio   0.69 (0.34 to 1.37) .29 
  Difference in 
percentage pointsa 
  −1.7 (−6.0 to 2.6) - 
Pleurodesis failure, 
No. of patients (%) at 
180 d 
46/161 (29) 44/159 (28)   
  Odds ratio   1.05 (0.63 to 1.73) .86 
  Difference in 
percentage pointsa 
  0.0 (−9.3 to 9.3) 1.00 
Time to pleurodesis 
failure within 180 d*, 
median (IQR) 
- - 1.01 (0.67 to 1.52) .98 
  All participants NR (91 to NR) [N 
= 161] 
NR (80 to NR) 
[N = 159] 
  
  Participants who 
experienced 
pleurodesis failure 
46 (26 to 78) [N = 
46] 
30 (21 to 59) [N 
= 44] 
  
All-cause mortality at 
180 d, No. of patients 
(%) 
66/165 (40) 68/163 (42)   
  Odds ratio   0.91 (0.58 to 1.44) .70 
  Difference in 
percentage pointsa 
  −1.1 (−11.3 to 9.1) .84 
Nights as hospital 
inpatient within 90 d, 
mean (SD); median 
(IQR) 
12.1 (13.0); 7 (4 
to 16) [N = 165] 
10.8 (10.0); 7 (4 
to 14) [N = 
162] 
  
  Rate ratio   1.11 (0.89 to 1.37) .35 
  Difference in meansa   1.2 (−1.3 to 3.7)  
Thoracic pain, mean 
(SD) change in VAS 
from baseline in mm, d 
N = 142 with ≥1 
measurement 




  Baseline 17.0 (23) [N = 
165] 
17.7 (25) [N = 
163] 
- - 
  7 1.0 (25) [N = 108] 2.3 (28) [N = 
98] 
−1.2 (−6.9 to 4.6) .69 
  30 −1.5 (25) [N = 
123] 
−5.6 (26) [N = 
124] 
1.2 (−3.5 to 6.0) .61 
 
 
  90 −2.5 (23) [N = 
91] 
−6.9 (24) [N = 
93] 
0.5 (−4.8 to 5.8) .85 
  180 −2.0 (23) [N = 
68] 
−6.2 (23) [N = 
69] 
0.8 (−4.6 to 6.2) .78 
Breathlessness, mean 
(SD) change in VAS 
from baseline in mm, d 
N = 142 with ≥1 
measurement 




  Baseline 53 (29) [N = 165] 53 (33) [N = 
163] 
- - 
  7 −31 (32) [N = 
106] 
−29 (35) [N = 
99] 
−2.0 (−8.0 to 4.0) .51 
  30 −28 (32) [N = 
123] 
−23 (39) [N = 
124] 
−4.4 (−11.1 to 2.3) .20 
  90 −25 (35) [N = 91] −29 (36) [N = 
93] 
2.1 (−5.4 to 9.6) .58 
  180 −30 (33) [N = 68] −29 (43) [N = 
68] 




(SD); median (IQR), d 
N = 125 with ≥1 
measurement 




  Baseline 54 (20) [N = 37] 47 (20) [N = 
37] 
- - 
  Tube removal 16 (12); 15 (7 to 
23) [N = 105] 
17 (15); 14 (5 
to 28) [N = 98] 
−0.8 (−4.5 to 2.9) .66 
  30 25 (19); 21 (10 to 
37) [N = 89] 
26 (18); 21 (13 
to 37) [N = 76] 
−1.5 (−6.7 to 3.7) .58 
  90 20 (19); 15 (5 to 
28) [N = 65] 
21 (19); 18 (6 
to 31) [N = 47] 
−2.5 (−8.9 to 3.9) .45 
  180 17 (14); 14 (4 to 
23) [N = 35] 
16 (13); 15 (6 
to 23) [N = 37] 
−0.8 (−6.7 to 5.1) .79 
EQ-5D-5L** utility, 
mean (SD), d 
    
  Baseline 0.57 (0.26) [N = 
163] 
0.55 (0.26) [N 
= 164] 
- - 
  30 0.60 (0.26) [N = 
132] 
0.60 (0.27) [N 
= 132] 
0.00 (−0.06 to 
0.07) 
.89 
  90 0.60 (0.29) [N = 
95] 
0.65 (0.27) [N 
= 100] 
−0.05 (−0.13 to 
0.04) 
.23 
  180 0.71 (0.22) [N = 
69] 
0.68 (0.26) [N 
= 72] 
0.04 (−0.04 to 
0.12) 
.31 
EQ-5D-5L VAS in 
mm, mean (SD), d 
    
  Baseline 50 (22) [N = 160] 50 (22) [N = 
164] 
- - 
  30 59 (23) [N = 132] 55 (25) [N = 
132] 
4 (−2 to 9) .24 
  90 63 (23) [N = 95] 60 (23) [N = 
98] 
3 (−4 to 9) .41 
 
 
  180 66 (23) [N = 70] 66 (21) [N = 
71] 
0 (7 to 8) .98 
SF-6D** utility, mean 
(SD), d 
    
  Baseline 0.58 (0.11) [N = 
157] 
0.56 (0.12) [N 
= 153] 
- - 
  30 0.59 (0.11) [N = 
125] 
0.60 (0.12) [N 
= 123] 
0.00 (−0.03 to 
0.03) 
.78 
  90 0.63 (0.11) [N = 
89] 
0.64 (0.14) [N 
= 96] 
0.00 (−0.04 to 
0.03) 
.90 
  180 0.65 (0.12) [N = 
67] 
0.64 (0.12) [N 
= 71] 
0.01 (−0.03 to 
0.05) 
.77 
Abbreviations: NR, Not reached; VAS, Visual Analogue Scale. 
All treatment effects are difference in means (standard deviation in parentheses), except 
for pleurodesis failure and all-cause mortality (odds ratios); time to pleurodesis (hazard 
ratio from a competing risk analysis with mortality was a competing risk); and nights in 
hospital (rate ratio). All treatment effects are adjusted for the minimisation factors. 
+ Unless otherwise stated 
^ All analyses adjusted for the minimization variables (underlying malignancy 
[mesothelioma, breast cancer, lung cancer, other] and WHO performance status [0-1, 2-
3]) by including them as fixed covariates in a regression model. P values were calculated 
directly from the adjusted regression model. 
a Post-hoc analysis. Differences in percentage points were estimated from a generalized 
linear model, with a binomial family and identity link. Difference in means was estimated 
from a linear regression model. All models were adjusted for the stratification factors. 
* 49/159 (31%) of patients in the control group and 42/161 (26%) patients in the 
intervention group died before experiencing pleurodesis failure, and 44 (28%) and 46 
(29%) in the control and intervention groups respectively experienced pleurodesis failure 
within 180 days of randomization. Analysis includes all patients (n = 159 slurry group, n 
= 161 poudrage group). The adjusted hazard ratio from a post-hoc Cox model which does 
not incorporate mortality as a competing risk was 1.01 (0.67 to 1.52). 
**EQ-5D-5L responses were converted into a utility score ranging from −0.59 to 1.00,25 
and scores on the visual-analogue scale range from 0 to 100, with higher scores 
indicating better quality of life. 
**For the SF-36, individual domains’ scores were transformed on to a scale from 0 
(worst health) to 100 (best health) before being converted into a SF-6D utility score 
ranging from 0.257 to 1.00, with higher scores indicating better quality of life 
Self-reported chest pain and dyspnea were measured using a visual-analogue scale 
running from 0 to 100mm, with a score of 0 indicating the complete absence of 
symptoms and 100 the maximum possible level of symptoms. The minimal clinically 
important difference (MCID) for dyspnea in MPE (using 0-100mm VAS scale) is 19mm 




Table 3. Summary of Reported Adverse Events 
 Thoracoscopy and 
Poudrage (179 Events) 
Chest Tube and 
Slurry (152 Events) 
Pneumonia/chest infection 25 19 
Disease progression, dyspnea due to fluid 23 20 
Other pleural intervention related, 
pneumothorax/bronchopleural fistula 
15 18 
Anemia 10 4 
Trial intervention relateda, Other/unspecified 10 7 
Medication/chemotherapy side effect 9 13 
Trial intervention relateda, pain 9 6 
Trial intervention relateda, surgical emphysema 9 2 
Disease progression, death 7 5 
Non-chest infection 7 5 
Pulmonary embolism 7 9 
Trial intervention relateda, pleural infection 6 0 
Disease progression, dyspnea not due to fluid 4 4 
Lung entrapment 4 1 
Trial intervention relateda, hypoxia 4 0 
Trial intervention relateda, 
pneumothorax/bronchopleural fistula 
3 4 
Trial intervention relateda, subcutaneous 
infection 
3 3 
Cardiac arrhythmia 2 2 
Trial intervention relateda, bleeding 2 1 
Tube dislodgement/accidental removal 2 9 
Trial intervention relateda, cough 1 0 
Otherb 17 20 
aCategorization and likelihood of an event being related to the trial was assessed by a 
blinded, independent pulmonologist 
bOther includes: Accidental injury, cerebrovascular event, disease progression (other), 
disease progression (metastasis), disease progression (nausea/vomiting), diseases 
progression (pain), indwelling pleural catheter blockage, abnormal blood test (other), 
other unspecified event, pleural infection (not trial related), venous thromboembolic 
event (not pulmonary embolism). 
See eTables S24-S29 in Supplement for full details of adverse and serious adverse events. 
